This is why PlexusDx emphasizes precision dosing: finding your therapeutic sweet spot rather than chasing maximum doses
doi: 10.1016/j.envint.2018.07.029 177 ZamoraANJansenECTamayo-OrtizMGoodrichJMSnchezBNWatkinsDJet al
Receptor trafficking or subcellular localization of GPCRs has functional implications for drug action
The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity
Stop and recheck your inputs vial strength, diluent volume, and prescribed dose before drawing anything